SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced six upcoming presentations on plazomicin at the Infectious Diseases Society of America (IDSA) IDWeek™ 2018, being held in San Francisco, CA from October 3 to 7, 2018.
The presentations are summarized below:
| Title: | Microbiological Outcomes with Plazomicin (PLZ) Versus Meropenem (MEM) in Patients (pts) with Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study |
| Authors: | Tiffany R. Keepers, Deborah S. Cebrik, Daniel J. Cloutier, Allison Komirenko, Lynn E. Connolly, Kevin M. Krause |
| Date: | Thursday, Oct 4 |
| Oral Presentation: | 124 |
| Title: | In vitro activity of plazomicin, a next-generation aminoglycoside, against carbapenemase-producing Klebsiella pneumoniae |
| Authors: | Michael R. Jacobs, Caryn E. Good, Ayman M. Abdelhamed, Daniel D. Rhoads, Kristine M. Hujer, Andrea M. Hujer, Susan D. Rudin, T. Nicholas Domitrovic, Lynn Connolly, Kevin M. Krause, Sandra S. Richter, David Van Duin, Barry N. Kreiswirth, Robert A. Bonomo, Antibiotic Resistance Leadership Group |
| Date: | Friday, October 5 |
| Poster: | 1348 |
| Title: | Mass Balance, Metabolism, and Excretion of Plazomicin in Healthy Human Subjects |
| Authors: | Taylor Choi, Julie D. Seroogy, Mitesh Sanghvi, Shyeilla V. Dhuria |
| Date: | Friday, October 5 |
| Poster: | 1400 |
| Title: | Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States |
| Authors: | Mariana Castanheira, Jennifer M. Streit, Alisa W. Serio, Kevin M. Krause, Robert K. Flamm |
| Date: | Friday, October 5 |
| Poster: | 1345 |
| Title: | Microbiological Outcomes with Plazomicin (PLZ) versus Colistin (CST) in Patients (pts) with Bloodstream Infections (BSI) Caused by Carbapenem-resistant- Enterobacteriaceae (CRE) in the CARE Study |
| Authors: | Alisa W. Serio, Alex Smith, Kevin M. Krause, Irene Galani, Ana C. Gales, Adrian Jubb, Lynn E. Connolly |
| Date: | Saturday, October 6 |
| Poster: | 1964 |
| Title: | Comparison of Plazomicin MIC Test Strip and Broth Microdilution MIC Results for 125 Enterobacteriaceae |
| Authors: | Laura Koeth, Jeanna DiFranco-Fisher, Alisa W. Serio |
| Date: | Saturday, Oct 6 |
| Poster: | 2060 |
The abstracts are available through the IDWeek website and posters will be available at: www.achaogen.com.
About Achaogen
Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen's first commercial product is ZEMDRITM (plazomicin), for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. Achaogen is also developing a new aminoglycoside program, which is supported by CARB-X. All product candidates are investigational, have not been determined to be safe or efficacious, and have not been approved for commercialization. For more information, visit the Achaogen website at www.achaogen.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential uses and advantages of ZEMDRI, Achaogen commercial objectives and the Achaogen pipeline of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Achaogen's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Achaogen business in general, see Achaogen current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 27, 2018, and its Quarterly Report on Form 10-Q filed on August 6, 2018. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances, or otherwise.
Source: Achaogen, Inc.
Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
arr@lifesciadvisors.com
Media Contact:
Martin Forrest
mforrest@achaogen.com